Sage stock trial#
Sage stock license#

Further, unlike other models with evenly weighted metrics, we assign context-sensitive relative weightings to our key metrics, based on market, regional, ownership or sector differences. Specifically, these ratings reflect actual corporate behaviors rather than policies or affirmations of intent to adhere to best ESG practices. Unlike traditional ESG risk models, MSCI's rating methodology is designed to identify risks most likely to affect equity valuations. The ESG Ratings model is based on a carefully crafted and applied list of KeyMetrics® that result in an overall ESG concern level as expressed by Red (High Concern), Yellow (Average Concern), and Green (Low Concern) flags. These ratings provide an independent assessment of the sustainable investment value of public companies. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Įnvironmental, Social, and Governance (ESG) Flags: MSCI Ratings publishes Environmental, Social and Governance (ESG) ratings on over 6,000 companies worldwide.

and changed its name to Sage Therapeutics, Inc. The company was formerly known as Sterogen Biopharma, Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products.

Sage stock license#

for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea and a collaboration and license agreement with Biogen MA Inc. has a strategic collaboration with Shionogi & Co., Ltd.

Sage stock trial#

In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders.